Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

NOAH outlines priorities for UK animal health sector
NOAH has stressed the need to ensure that measures are in place to facilitate trade and innovation in the animal medicines sector.
Organisation stresses need to ensure measures are in place to facilitate trade

The priorities needed to deliver a thriving animal health sector following the UK’s exit from the EU have been outlined by the National Office of Animal Health (NOAH).

Following NOAH’s board meeting on 1 November, chair Cat Sayer said: “The UK must continue to be a vibrant and innovative animal health market, providing opportunities for animal medicines businesses to thrive.

“We are in a strong position in the UK to be a global centre of excellence for animal medicines, supporting both innovative product developments and a regulatory model to benefit both local and international trade.

“We need to ensure that our industry’s needs and priorities are included in discussions on how the UK exit develops,” she said.

After the UK leaves the EU, NOAH stresses the need to ensure that measures are in place to facilitate trade and innovation in the animal medicines sector.

They add that future UK regulation of veterinary medicines must incentivise product research and development - an environment where companies are encouraged to do business in the UK.

“The health and welfare of British animals, as well as our public health and food safety need to be safeguarded – our vets and animal keepers need to continue to have access to a wide range of appropriate animal medicines.

“And we must not forget our people. The animal medicines industry has many highly skilled roles. Businesses will continue to need to be able to recruit the best,” said Ms Sayer.

To identify both the risks and opportunities offered by the UK in the wake of leaving the EU, NOAH has formed a Brexit Task Force. Covering the breadth of the UK animal medicines sector, the group includes both UK based and company heads.

Furthermore, Noah is joining forces with partners across the animal health sector and engaging with relevant government departments to ensure that veterinary medicines are included in future government industrial strategy.

“In the UK consumers both encourage and expect high standards of animal welfare in food production and pet owners also want prompt and effective care.  UK veterinary surgeons and animal owners need access to a full range of medicines and vaccines to protect animal welfare by preventing disease and treating illness effectively,” added Cat.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.